## Gene Summary
The LDLR gene encodes the low-density lipoprotein receptor, which is crucial for the regulation of cholesterol levels in the body. The receptor binds to low-density lipoproteins (LDL), commonly known as 'bad' cholesterol, enabling their uptake and removal from the bloodstream, thereby preventing the formation of cholesterol plaques in arteries. LDLR is predominantly expressed in the liver, adrenal glands, and kidneys, with its activity being highly influential in overall cardiovascular health.

## Gene Drugs, Diseases, Phenotypes, and Pathways
Mutations in the LDLR gene are primarily associated with Familial Hypercholesterolemia (FH), a genetic disorder characterized by high cholesterol levels, specifically elevated levels of LDL cholesterol, and an increased risk of coronary artery disease. Common phenotypes include xanthomas and premature cardiovascular disease. The biochemical pathway primarily involving LDLR is the cholesterol biosynthesis and metabolism pathway. The proper function of LDLR is critical for the prevention of atherosclerosis and related cardiovascular diseases.

## Pharmacogenetics
The pharmacogenetics of LDLR primarily involves its direct role in modulating the efficacy and response of lipid-lowering therapies. Statins, a class of drugs widely prescribed to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, indirectly affect LDLR expression by increasing the number of LDL receptors on the liver cells, thus enhancing the clearance of circulating LDL. Commonly used statins include atorvastatin, simvastatin, and rosuvastatin. The response to statins can vary significantly depending on the genetic variants of the LDLR gene present in an individual, impacting treatment outcomes in terms of cholesterol reduction and cardiovascular risk management. This makes LDLR an important target in personalized medicine approaches for managing hypercholesterolemia and preventing coronary artery disease.